文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

原发性骨髓纤维化与MDS伴骨髓纤维化患者纤维驱动细胞的比较

[Fibrosis-driving cells in patients with primary myelofibrosis and myelodysplastic syndromes with myelofibrosis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该研究比较初诊PMF与MDS-MF患者骨髓活检中纤维驱动细胞的差异。结果显示PMF患者α-SMA(+)细胞来源于Gli1(+)和LeptinR(+)细胞,而MDS-MF患者仅来源于Gli1(+)细胞;MF-2/3级PMF患者ProcollagenⅠ(+)/CD45(+)细胞计数显著高于MDS患者。

要点

  • PMF的α-SMA(+)细胞来源包括Gli1(+)和LeptinR(+)细胞,MDS-MF仅来自Gli1(+)细胞
  • MF-2/3级PMF患者ProcollagenⅠ(+)/CD45(+)细胞计数显著高于MDS患者
  • MF分级及纤维驱动细胞计数与PMF和MDS患者总生存无相关性

核心结论

  • PMF患者α-SMA(+)细胞来源于Gli1(+)和LeptinR(+)细胞,而MDS-MF患者α-SMA(+)细胞仅来源于Gli1(+)细胞。
  • MF-2/3级患者中PMF的ProcollagenⅠ(+)/CD45(+)细胞计数显著高于MDS-MF患者(P=0.007)。

研究设计与样本

  • 骨髓活检组织切片免疫荧光研究,随机选取初诊PMF和MDS患者各10例,覆盖MF-0/1、MF-2和MF-3级。
  • 利用特异性免疫荧光抗体标记Gli1、LeptinR、α-SMA、CD45和ProcollagenⅠ,共聚焦显微镜成像后以Fiji-ImageJ计数。

主要发现

  • MF-2/3级PMF和MDS患者LeptinR(+)、α-SMA(+)、α-SMA(+)/Gli1(+)和ProcollagenⅠ(+)/CD45(+)细胞计数均显著高于MF-0/1级患者(P<0.05)。
  • MF-2/3级PMF患者Gli1(+)和α-SMA(+)/LeptinR(+)细胞计数显著高于MF-0/1级PMF患者(P=0.001和0.006)。
  • MDS患者MF-0/1与MF-2/3级间Gli1(+)和α-SMA(+)/LeptinR(+)细胞计数差异无统计学意义(P=0.169和0.067)。
  • MF-0/1级患者中PMF与MDS所有纤维驱动细胞计数差异均无统计学意义(P>0.05)。
  • MF-2/3级患者中PMF的ProcollagenⅠ(+)/CD45(+)计数显著高于MDS(P=0.007),其他纤维驱动细胞计数差异无统计学意义(P>0.05)。

临床怎么用

  • 提示PMF与MDS-MF的纤维驱动细胞来源不同,可为鉴别两类疾病及理解纤维化机制提供依据。
  • 纤维驱动细胞计数与总生存无相关性,暂不宜作为预后评估指标。

局限性

  • 每组随机选取10例,样本量较小。
  • MF分级及纤维驱动细胞计数与总生存无相关性,未提供生存分析的具体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare fibrosis-driving cells in patients with primary myelofibrosis (PMF) and patients with myelodysplastic syndromes (MDS) with myelofibrosis (MF) (MDS-MF) . Methods: Bone marrow biopsy sections of patients with newly diagnosed PMF and MDS (10 each randomly selected for MF-0/1, MF-2, and MF-3) were stained with specific immunofluorescence antibodies to label Gli1, LeptinR, alpha smooth muscle actin (α-SMA) , CD45, and ProcollagenⅠ. Images captured by confocal microscopy were analyzed by Fiji-ImageJ to calculate the cell counts of Gli1(+), LeptinR(+) cells, and fibrosis-driving cells including α-SMA(+), α-SMA(+)/Gli1(+), α-SMA(+)/LeptinR(+), and ProcollagenⅠ(+)/CD45(+) cells. Results: Patients with PMF and MDS with MF-2/3 had higher LeptinR(+), α-SMA(+), α-SMA(+)/Gli1(+), and Procollagen Ⅰ(+)/CD45(+) cell counts compared with those with MF-0/1 (all P values<0.05) . However, patients with PMF with MF-2/3 presented with higher Gli1(+) and α-SMA(+)/LeptinR(+) cell counts than those with MF-0/1 (P=0.001 and 0.006) , whereas these cells were similar between patients with MDS with MF-0/1 and MF-2/3 (P=0.169 and 0.067) . In patients with MF-0/1, all fibrosis-driving cells did not differ between PMF and MDS (all P>0.05) . However, in patients with MF-2/3, Procollagen Ⅰ(+)/CD45(+) cell counts were higher in patients with PMF compared with those with MDS (P=0.007) , while other fibrosis-driving cell counts were similar between these two groups (all P>0.05) . MF grade and fibrosis-driving cell counts were not correlated with overall survival in patients with either PMF or MDS. Conclusion: α-SMA(+) cells in patients with PMF originated from both Gli1(+) and LeptinR(+) cells, whereas α-SMA(+) cells in patients with MDS-MF only originated from Gli1(+) cells; patients with PMF had higher ProcollagenⅠ(+)/CD45(+) cell counts than those with MDS-MF. 目的: 比较原发性骨髓纤维化(PMF)和骨髓增生异常综合征伴骨髓纤维化(MDS-MF)患者纤维驱动细胞的差异。 方法: 随机选取MF-0/1、MF-2和MF-3级的初诊PMF和MDS患者各10例,骨髓活检组织切片利用特异性免疫荧光抗体标记Gli1、LeptinR、平滑肌肌动蛋白(α-SMA)、CD45和Procollagen Ⅰ,共聚焦显微镜成像后利用Fiji-ImageJ软件计数Gli1(+)、LeptinR(+)细胞及α-SMA(+)、α-SMA(+)/Gli1(+)、α-SMA(+)/LeptinR(+)和ProcollagenⅠ(+)/CD45(+)等纤维驱动细胞。 结果: MF-2/3级PMF和MDS患者LeptinR(+)、α-SMA(+)、α-SMA(+)/Gli1(+)和ProcollagenⅠ(+)/CD45(+)等细胞计数均显著高于MF-0/1级患者(P<0.05)。但MF-2/3级PMF患者Gli1(+)、α-SMA(+)/LeptinR(+)细胞计数显著高于MF-0/1级PMF患者(P值分别为0.001、0.006),而MDS患者中两组患者两群细胞计数差异无统计学意义(P值分别为0.169、0.067)。MF-0/1级患者中,PMF与MDS患者所有纤维驱动细胞计数相比差异均无统计学意义(P>0.05)。但MF-2/3级患者中,PMF患者ProcollagenⅠ(+)/CD45(+)计数显著高于MDS患者(P=0.007),其他纤维驱动细胞计数相比较差异均无统计学意义(P>0.05)。MF分级及纤维驱动细胞计数与PMF和MDS患者总生存时间无相关性。 结论: PMF患者α-SMA(+)细胞来源于Gli1(+)和LeptinR(+)细胞,而MDS-MF患者α-SMA(+)细胞仅来源于Gli1(+)细胞;PMF患者ProcollagenⅠ(+)/CD45(+)细胞计数显著高于MDS-MF患者。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Cai YN, Zhang PH, Fang LH, et al. [Fibrosis-driving cells in patients with primary myelofibrosis and myelodysplastic syndromes with myelofibrosis]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33445847. doi:10.3760/cma.j.issn.0253-2727.2020.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。